NASDAQ:EWTX Edgewise Therapeutics (EWTX) Stock Forecast, Price & News $6.20 +0.03 (+0.49%) (As of 09/20/2023 ET) Add Compare Share Share Today's Range$6.08▼$6.3950-Day Range$6.17▼$7.6952-Week Range$5.53▼$11.48Volume70,388 shsAverage Volume128,432 shsMarket Capitalization$393.45 millionP/E RatioN/ADividend YieldN/APrice Target$27.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Edgewise Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside335.5% Upside$27.00 Price TargetShort InterestBearish13.91% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.01Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.58) to ($1.96) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.72 out of 5 starsMedical Sector816th out of 962 stocksPharmaceutical Preparations Industry387th out of 450 stocks 3.5 Analyst's Opinion Consensus RatingEdgewise Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $27.00, Edgewise Therapeutics has a forecasted upside of 335.5% from its current price of $6.20.Amount of Analyst CoverageEdgewise Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted13.91% of the float of Edgewise Therapeutics has been sold short.Short Interest Ratio / Days to CoverEdgewise Therapeutics has a short interest ratio ("days to cover") of 26.9, which indicates bearish sentiment.Change versus previous monthShort interest in Edgewise Therapeutics has recently increased by 1.11%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldEdgewise Therapeutics does not currently pay a dividend.Dividend GrowthEdgewise Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EWTX. Previous Next 3.3 News and Social Media Coverage News SentimentEdgewise Therapeutics has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Edgewise Therapeutics this week, compared to 1 article on an average week.Search Interest3 people have searched for EWTX on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Edgewise Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders31.95% of the stock of Edgewise Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Edgewise Therapeutics are expected to decrease in the coming year, from ($1.58) to ($1.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edgewise Therapeutics is -4.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Edgewise Therapeutics is -4.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEdgewise Therapeutics has a P/B Ratio of 1.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Edgewise Therapeutics (NASDAQ:EWTX) StockEdgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company also develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The Company was incorporated in 2017 and is headquartered in Boulder, Colorado.Read More EWTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EWTX Stock News HeadlinesSeptember 21, 2023 | americanbankingnews.comBrokers Issue Forecasts for Edgewise Therapeutics, Inc.'s Q3 2023 Earnings (NASDAQ:EWTX)September 14, 2023 | finance.yahoo.comEdgewise Therapeutics Begins Dosing First-in-Human Phase 1 Trial of EDG-7500, its Lead Clinical Candidate for Hypertrophic Cardiomyopathy (HCM) and Other Serious Diseases of Cardiac Diastolic DysfunctionSeptember 21, 2023 | Wall Street Fundamentals (Ad)How is This "Hidden Gem" Thriving in a Turbulent Market?While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.September 5, 2023 | finance.yahoo.comWall Street Analysts Think Edgewise Therapeutics, Inc. (EWTX) Could Surge 327.91%: Read This Before Placing a BetAugust 16, 2023 | markets.businessinsider.comWhere Edgewise Therapeutics Stands With AnalystsAugust 16, 2023 | finance.yahoo.comWall Street Analysts Believe Edgewise Therapeutics, Inc. (EWTX) Could Rally 224.25%: Here's is How to TradeAugust 14, 2023 | markets.businessinsider.comEdgewise Therapeutics (EWTX) Receives a Buy from Truist FinancialJuly 17, 2023 | finance.yahoo.comWe're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash WiselySeptember 21, 2023 | Wall Street Fundamentals (Ad)How is This "Hidden Gem" Thriving in a Turbulent Market?While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.July 6, 2023 | msn.comEdgewise Therapeutics (EWTX) Price Target Increased by 19.66% to 28.56June 29, 2023 | msn.comRBC Capital Reiterates Edgewise Therapeutics (EWTX) Outperform RecommendationJune 27, 2023 | msn.comTruist Securities Reiterates Edgewise Therapeutics (EWTX) Buy RecommendationJune 27, 2023 | markets.businessinsider.comTruist Financial Sticks to Its Buy Rating for Edgewise Therapeutics (EWTX)June 27, 2023 | markets.businessinsider.comEdgewise Therapeutics (EWTX) Gets a Sell from Goldman SachsJune 27, 2023 | msn.comCIRCOR International, Enovix, Edgewise Therapeutics And Other Big Stocks Moving Higher On TuesdayJune 26, 2023 | finance.yahoo.comEdgewise Therapeutics Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)June 6, 2023 | finance.yahoo.comEdgewise Therapeutics to Present at the Goldman Sachs Global Healthcare ConferenceMay 16, 2023 | msn.comJP Morgan Maintains Edgewise Therapeutics (EWTX) Overweight RecommendationMay 12, 2023 | msn.comWedbush Reiterates Edgewise Therapeutics (EWTX) Outperform RecommendationMay 12, 2023 | markets.businessinsider.comRBC Capital Reaffirms Their Buy Rating on Edgewise Therapeutics (EWTX)May 11, 2023 | msn.comEdgewise Therapeutics: Q1 Earnings InsightsMay 1, 2023 | markets.businessinsider.comFlexing On Muscular Dystrophy, Analyst Expects Almost 200% Upside For Edgewise TherapeuticsMay 1, 2023 | msn.comBenzinga's Top Ratings Upgrades, Downgrades For May 1, 2023May 1, 2023 | msn.comTruist Securities Initiates Coverage of Edgewise Therapeutics (EWTX) with Buy RecommendationMarch 30, 2023 | finance.yahoo.comEdgewise Therapeutics Announces Journal of Clinical Investigation Publication of Key Preclinical Data Linking Modulation of Fast Skeletal Muscle Contraction to Protection of Skeletal Muscle in Models of Duchenne Muscular Dystrophy (DMD)March 21, 2023 | finance.yahoo.comEdgewise Therapeutics to Present at the Stifel 2023 CNS Days on March 28, 2023March 14, 2023 | finance.yahoo.comEdgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2023 Annual MDA Clinical and Scientific ConferenceSee More Headlines Receive EWTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edgewise Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address EWTX Company Calendar Last Earnings8/10/2023Today9/21/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EWTX CUSIPN/A CIK1710072 Webwww.edgewisetx.com Phone720-262-7002FaxN/AEmployees74Year FoundedN/APrice Target and Rating Average Stock Price Forecast$27.00 High Stock Price Forecast$29.00 Low Stock Price Forecast$25.00 Forecasted Upside/Downside+335.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-67,640,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-24.09% Return on Assets-22.86% Debt Debt-to-Equity RatioN/A Current Ratio22.01 Quick Ratio22.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.48 per share Price / Book1.13Miscellaneous Outstanding Shares63,460,000Free Float43,184,000Market Cap$393.45 million OptionableNot Optionable Beta-0.26 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Peter A. Thompson FACP (Age 63)M.D., Co-Founder & Independent Chairman Comp: $73kDr. Kevin Koch Ph.D. (Age 63)Pres, CEO & Director Comp: $913.1kDr. Badreddin Edris Ph.D. (Age 36)Co-Founder & Independent Director Comp: $40kDr. Alan J. Russell Ph.D. (Age 53)Co-Founder, Chief Scientific Officer & Director Comp: $657.52kDr. Joanne M. Donovan M.D. (Age 66)Ph.D., Chief Medical Officer Comp: $695.48kMr. R. Michael Carruthers (Age 65)Chief Financial Officer Mr. John R. Moore (Age 59)Gen. Counsel Dr. Behrad Derakhshan Ph.D. (Age 43)Chief Bus. Officer Dr. Marc Semigran M.D. (Age 66)Chief Devel. Officer More ExecutivesKey CompetitorsLyell ImmunopharmaNASDAQ:LYELCOMPASS PathwaysNASDAQ:CMPSUroGen PharmaNASDAQ:URGNArcutis BiotherapeuticsNASDAQ:ARQTAldeyra TherapeuticsNASDAQ:ALDXView All CompetitorsInsiders & InstitutionsPoint72 Asset Management L.P.Bought 107,100 shares on 8/15/2023Ownership: 0.169%Alliancebernstein L.P.Bought 7,930 shares on 8/15/2023Ownership: 0.053%Wells Fargo & Company MNBought 9,527 shares on 8/15/2023Ownership: 0.026%Royal Bank of CanadaBought 2,339 shares on 8/15/2023Ownership: 0.008%Citadel Advisors LLCSold 3,700 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions EWTX Stock - Frequently Asked Questions Should I buy or sell Edgewise Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edgewise Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EWTX shares. View EWTX analyst ratings or view top-rated stocks. What is Edgewise Therapeutics' stock price forecast for 2023? 4 analysts have issued 12-month price objectives for Edgewise Therapeutics' shares. Their EWTX share price forecasts range from $25.00 to $29.00. On average, they expect the company's stock price to reach $27.00 in the next year. This suggests a possible upside of 335.5% from the stock's current price. View analysts price targets for EWTX or view top-rated stocks among Wall Street analysts. How have EWTX shares performed in 2023? Edgewise Therapeutics' stock was trading at $8.94 at the start of the year. Since then, EWTX shares have decreased by 30.6% and is now trading at $6.20. View the best growth stocks for 2023 here. When is Edgewise Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our EWTX earnings forecast. How were Edgewise Therapeutics' earnings last quarter? Edgewise Therapeutics, Inc. (NASDAQ:EWTX) released its quarterly earnings results on Thursday, August, 10th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.07. What ETF holds Edgewise Therapeutics' stock ? iShares Neuroscience and Healthcare ETF holds 4,907 shares of EWTX stock, representing 0.70% of its portfolio. When did Edgewise Therapeutics IPO? (EWTX) raised $150 million in an IPO on Friday, March 26th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, SVB Leerink and Wedbush PacGrow served as the underwriters for the IPO. What is Edgewise Therapeutics' stock symbol? Edgewise Therapeutics trades on the NASDAQ under the ticker symbol "EWTX." Who are Edgewise Therapeutics' major shareholders? Edgewise Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.95%), Deep Track Capital LP (4.33%), Goldman Sachs Group Inc. (2.76%), Geode Capital Management LLC (1.35%), State Street Corp (1.18%) and Granahan Investment Management LLC (1.02%). Insiders that own company stock include Alan J Russell, Behrad Derakhshan, Holdings A/S Novo, James E Flynn, Joanne M Donovan, John R Moore, Jonathan D Root, Kevin Koch, Orbimed Advisors Llc, Peter A Thompson and R Michael Carruthers. View institutional ownership trends. How do I buy shares of Edgewise Therapeutics? Shares of EWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Edgewise Therapeutics' stock price today? One share of EWTX stock can currently be purchased for approximately $6.20. How much money does Edgewise Therapeutics make? Edgewise Therapeutics (NASDAQ:EWTX) has a market capitalization of $393.45 million. The company earns $-67,640,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis. How can I contact Edgewise Therapeutics? Edgewise Therapeutics' mailing address is 3415 COLORADO AVE., BOULDER CO, 80303. The official website for the company is www.edgewisetx.com. The company can be reached via phone at 720-262-7002 or via email at ir@edgewisetx.com. This page (NASDAQ:EWTX) was last updated on 9/21/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edgewise Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.